Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Return on Sales (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Return on Sales for 7 consecutive years, with 167.7% as the latest value for Q1 2026.

  • For Q1 2026, Return on Sales fell 10549.0% year-over-year to 167.7%; the TTM value through Mar 2026 reached 1539.24%, down 153496.0%, while the annual FY2024 figure was 4.09%, 8749.0% up from the prior year.
  • Return on Sales hit 167.7% in Q1 2026 for Barinthus Biotherapeutics, up from 209.65% in the prior quarter.
  • Across five years, Return on Sales topped out at 1.33% in Q3 2022 and bottomed at 21126.0% in Q2 2025.
  • Average Return on Sales over 5 years is 1389.68%, with a median of 50.57% recorded in 2023.
  • On a YoY basis, Return on Sales climbed as much as 48255bps in 2022 and fell as far as -1672128bps in 2022.
  • Barinthus Biotherapeutics' Return on Sales stood at 3.28% in 2022, then plummeted by -2694bps to 91.58% in 2023, then soared by 96bps to 4.09% in 2024, then crashed by -5029bps to 209.65% in 2025, then increased by 20bps to 167.7% in 2026.
  • According to Business Quant data, Return on Sales over the past three periods came in at 167.7%, 209.65%, and 239.58% for Q1 2026, Q4 2025, and Q3 2025 respectively.